Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using the quantiFERON®-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital

Journal of Medical Virology

Volumn 82, Issue 3, 2010, Pages 433-440

  Fleming, T ^a,b   Dunne, J ^b   Crowley, B ^a,b,c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Ex vivo IFN ; HCMV specific CD8+ T cells; Immunocompromised; QuantiFERON CMV

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; VIRUS ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER PATIENT; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DONOR; EX VIVO STUDY; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HISTOCOMPATIBILITY; HOSPITAL PATIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; IRELAND; LYMPHOCYTOPOIESIS; MAJOR CLINICAL STUDY; PATIENT CODING; PATIENT MONITORING; RECIPIENT; RISK ASSESSMENT; SEROLOGY; SIBLING; T LYMPHOCYTE; VALIDATION PROCESS;

CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALS; HUMANS; IMMUNOASSAY; IMMUNOCOMPROMISED HOST; IRELAND; VIREMIA;

HUMAN HERPESVIRUS 5;

EID: 75449114280     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21727     Document Type: Article

References (25)

1. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L. 2003. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity. Blood 101:407-414.
2. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, Goldman J, Craddock C, Moss PA. 2001. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97:1232-1240.
3. Ganepola S, Gentilini C, Hilbers U, Lange T, Rieger K, Hofmann J, Maier M, Liebert UG, Niederwieser D, Engelmann E, Heilbronn R, Thiel E, Uharek L. 2007. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 39:293-299.
4. Ghanekar SA, Nomura LE, Suni MA, Picker LJ, Maecker HT, Maino VC. 2001. Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin Diagn Lab Immunol 8:628-631.
5. Grob JP, Grundy JE, Prentice HG, Griffiths PD, Hoffbrand AV, Hughes MD, Tate T, Wimperis JZ, Brenner MK. 1987. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1:774-776.
6. Guiver M, Fox AJ, Mutton K, Mogulkoc N, Egan J. 2001. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients. Transplantation 71:1609-1615.
7. Harari A, Zimmerli SC, Pantaleo G. 2004. Cytomegalovirus (CMV)-specific cellular immune responses. Hum Immunol 65:500-506.
8. Kapp M, Tan SM, Einsele H, Grigoleit G. 2007. Adoptive immunotherapy of HCMV infection. Cytotherapy 9:699-711.
9. Lacey SF, Gallez-Hawkins G, Crooks M, Martinez J, Senitzer D, Forman SJ, Spielberger R, Zaia JA, Diamond DJ. 2002. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 74:722-732.
10. Lacey SF, Diamond DJ, Zaia JA. 2004. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 10:433-447.
11. Lafarge X, Merville P, Cazin MC, Berge F, Potaux L, Moreau JF, Dechanet-Merville J. 2001. Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role. J Infect Dis 184:533-541.
12. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. 2003. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: An EBMT megafile analysis. Blood 102:4255-4260.
13. Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaud P, Ward K. 2004. Management of CMV infections: Recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 33:1075-1081.
14. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, Persaud N, Trigona W, Fu TM, Sinclair E, Bredt BM, McCune JM, Maino VC, Kern F, Picker LJ. 2001. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 255:27-40.
15. Montagna D, Locatelli F, Moretta A, Lisini D, Previdere C, Grignani P, DeStefano P, Giorgiani G, Montini E, Pagani S, Comoli P, Maccario R. 2004. T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. Blood 103:4322-4329.
16. Peggs KS, Verfuerth S, Pizzey A, Khan N, Moss P, Goldstone AH, Yong K, Mackinnon S. 2003. Reconstitution of T-cell repertoire after autologous stem cell transplantation: Influence of CD34 selection and cytomegalovirus infection. Biol Blood Marrow Transplant 9:198-205.
17. Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E. 1996. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: Significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 87:3984-3992.
18. Ruell J, Barnes C, Mutton K, Foulkes B, Chang J, Cavet J, Guiver M, Menasce L, Dougal M, Chopra R. 2007. Active CMV disease does not always correlate with viral load detection. Bone Marrow Transplant 40:55-61.
19. Schermann CM, Fischer G, Witt V, Kurz M, Potschger U, Fritsch G. 2008. Detection of human cytomegalovirus-specific T lymphocytes in human blood: Comparison of twomethods. Cytotherapy 10:834-841.
20. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ. 2005. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202:673-685.
21. Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M, Bell S, Gailbraith A, McNeil K, Jones S, Khanna R. 2007. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 9:165-170.
22. Westall GP, Mifsud NA, Kotsimbos T. 2008. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 8:1749-1754.
23. Williams KM, Gress RE. 2008. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 21:579-596.
24. Wimperis JZ, Brenner MK, Prentice HG, Reittie JE, Karayiannis P, Griffiths PD, Hoffbrand AV. 1986. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1:339-343.
25. Yang R, Xia T, Xu G, Li Z, Ying Z, Xu X. 2008. Human cytomegalovirus specific CD8(+) T lymphocytes display interferon-gamma secretion impairment in kidney transplant recipients with pp65 antigenemia. Transpl Proc 40:3500-3504.